Loading clinical trials...

Effects of Lipid Emulsions on Coagulation | Clinical Trials | Clareo Health

COMPLETED

Effects of Lipid Emulsions on Coagulation

Effects of Intravenous Lipid Emulsions on Coagulation Function: A Multicenter Observational Study

NCT07470385•Mimi Tang, PhD

Summary

The goal of this observational study is to learn how intravenous lipid emulsions may affect blood clotting function in hospitalized patients. The main question it aims to answer is: Does receiving intravenous lipid emulsions change blood clotting function in hospitalized patients? Inpatients who received intravenous lipid emulsions as part of their regular medical care during hospitalization will be included in this study. Information about their blood clotting function before and after lipid emulsion use will be collected from existing hospital records and compared with patients who did not receive lipid emulsions. This study will not change or add to the medical care patients receive.

Eligibility

Age

All ages

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•Patients who received intravenous lipid emulsion therapy for a total duration of ≥ 5 days during hospitalization.
•Lipid emulsions include single-bottle lipid emulsion injections and commercially available three-chamber parenteral nutrition admixtures containing lipid emulsions.
•Lipid emulsions do not include anesthetic-containing formulations, such as medium- or long-chain triglyceride lipid emulsions used in propofol.

Exclusion Criteria

•Patients who underwent major surgery with total blood loss exceeding 500 mL.
•Patients with malignant tumors who were receiving radiotherapy, chemotherapy, or immunotherapy during hospitalization.
•Patients with long-term use of anticoagulants or other medications known to affect coagulation function.
•Patients with active bleeding, any known coagulation or bleeding disorders, autoimmune diseases (e.g., primary immune thrombocytopenia), hematologic diseases (including thrombocytopenic purpura, megaloblastic anemia, aplastic anemia, or hematologic malignancies), or acquired immunodeficiency diseases.
•Patients who received blood transfusions during hospitalization.
•Patients with incomplete or missing clinical records.

Locations (1)

Department of Pharmacy, Xiangya Hospital, Central South University

Changsha, Hunan, China

Key Dates

Start Date

May 23, 2025

Primary Completion Date

September 20, 2025

Completion Date

September 20, 2025

Last Updated

March 13, 2026

Enrollment

6,259

ACTUAL participants

Conditions

Coagulation DisorderCoagulation Function

Interventions

Lipid Emulsion

DRUG

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

NCT05156983

Coagulation Disorder

View study

RECRUITING

Transfusion Surveillance in Anaesthesia

NCT06403163

Transfusion ReactionTransfusion Related Complication+6 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 13, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

Effects of Lipid Emulsions on Coagulation

Inclusion Criteria

Exclusion Criteria

A Study of TAK-330 to Reverse the Effects of Factor Xa Inhibitors For Adults Needing Urgent Surgery

Transfusion Surveillance in Anaesthesia

Evaluation of Hemostasis in Bleeding and Thrombotic Disorders

Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin

THrombo-Embolic Event in Onco-hematology

Coagulation in Acute Aortic Dissection